Τίτλος:
Nab-paclitaxel as second-line treatment in advanced gastric cancer: A multicenter phase II study of the hellenic oncology research group
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background This study evaluated the safety and efficacy of nab-paclitaxel as second-line treatment in patients with advanced gastric adenocarcinoma. Methods Thirty-nine pretreated patients [33 with taxane-based regimens (docetaxel, cisplatin, and fluorouracil)] and 6 with combination of fluoropyrimidines plus cisplatin with locally advanced inoperable and metastatic gastric and gastroesophageal junction adenocarcinoma were treated with weekly nab-paclitaxel (150 mg/m2 d1, d8, d15 in cycles of 28 days). Results Partial response (PR) was documented in nine patients (23.1%; 95% confidence interval 10.1-37.2%), stable disease (SD) in 11 (28.2%) and disease progression in 18 (46.2%). The disease control rate (SD + PR + complete response) was 51.3%. Grade 3 and 4 neutropenia occurred in 10.2% and 5.1% of patients, respectively; grade 3 anemia in 5.1%; grade 3 neurotoxicity in 5.1%; and grade 2 pain in 5.1%. The median progression-free survival was 3.0 months (range 0.3-13.6) and the median overall survival 6.8 months (range 0.3-22). Conclusion Nab-paclitaxel as second-line treatment in locally advanced inoperable or metastatic gastric and gastroesophageal junction carcinoma is an active chemotherapy regimen with a manageable toxicity profile and merits further evaluation. © 2018 Hellenic Society of Gastroenterology
Συγγραφείς:
Katsaounis, P.
Kotsakis, A.
Kentepozidis, N.
Polyzos, A.
Bakogeorgos, M.
Koinis, F.
Vamvakas, L.
Vardakis, N.
Kalbakis, K.
Boukovinas, I.
Varthalitis, I.I.
Prinarakis, E.
Georgoulias, V.
Souglakos, J.
Περιοδικό:
Annals of Gastroenterological Surgery
Εκδότης:
Hellenic Society of Gastroenterology
Λέξεις-κλειδιά:
cisplatin; docetaxel; fluoropyrimidine derivative; fluorouracil; paclitaxel, adult; aged; alopecia; anemia; Article; cancer chemotherapy; clinical article; constipation; dermatitis; drug dose reduction; drug efficacy; drug safety; esophageal adenocarcinoma; fatigue; female; gastroesophageal junction adenocarcinoma; Greece; human; hyperglycemia; leukopenia; lymphocytopenia; male; medication compliance; mucosa inflammation; multicenter study; multiple cycle treatment; nausea; neurotoxicity; neutropenia; open study; overall survival; pain; patient compliance; phase 2 clinical trial; progression free survival; respiratory tract infection; stomach adenocarcinoma; stomach cancer; thrombocytopenia; vomiting
DOI:
10.20524/aog.2017.0215
